Clinical Trials Browser

INDUSTRY × Rituximab × Dermatologic × Clear all

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT01994382 2022-04-05

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Phase 1/2 Completed

260 enrolled 33 charts

DermatologicLymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT01307267 2020-03-17

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Phase 1 Completed

190 enrolled 65 charts

DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Lymphoma, Large B-Cell, Diffuse